Navidea Biopharmaceuticals Inc P / E
Was ist das P / E von Navidea Biopharmaceuticals Inc?
P / E von Navidea Biopharmaceuticals Inc ist N/A
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Navidea Biopharmaceuticals Inc
Was macht Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Unternehmen mit p / e ähnlich Navidea Biopharmaceuticals Inc
- Adamis Pharmaceuticals hat P / E von N/A
- Scotgold Resources hat P / E von N/A
- FSD Pharma Inc hat P / E von N/A
- Revolution Bars Plc hat P / E von N/A
- First Foods hat P / E von N/A
- Tritent International hat P / E von N/A
- Navidea Biopharmaceuticals Inc hat P / E von N/A
- Syncora hat P / E von N/A
- YogaWorks hat P / E von N/A
- Naked Brand hat P / E von N/A
- Andover Mining hat P / E von N/A
- Le Chateau hat P / E von N/A
- Bonavista hat P / E von N/A